Warner-lambert Company

Reata Pharmaceuticals, Inc.

Brian Edward Kornberg

Sham Shridhar Nikam

Michael Francis Rafferty

Annette M Doherty

Chitase Lee

Po-wai Yuen

Xue-min Cheng

Edward Faith Elslager

Leslie M Werbel

Daniele Marie Leonard

Kyunghye Ahn

Xin Jiang

Melean Visnick

Bradley W Caprathe

Gary Louis Bolton

David Douglas Manning

Christopher F Bender

Ian Leslie Scott

Russell Andrew Lewthwaite

Martha R Hotema

Zachary S Sheldon

Disclosed herein are compounds of the formulas: as well as analogs thereof, wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used to inhibit ROR&#x3b3; and/or reduce the expression of IL-17. Also provided are methods of administering compounds and composition provided herein to a patient in need thereof, for example, for the treatment or prevention of diseases or disorders associated with inflammation or autoimmune disorders. 

Pyrimidine tricyclic enone derivatives for inhibition of ROR-gamma and other uses

Piperidine derivatives as subtype selective N-Methyl-D-Aspartate antagonists

Conformationally semi-constrained quinoxaline 2,3-diones as neuroprotective agents

A novel series of substituted quinoxaline 2,3-diones useful as neuroprotective agents are taught. Novel intermediates, processes of preparation, and pharmaceutical compositions containing the compounds are also taught. The compounds are glutamate antagonists and are useful in the treatment of stroke, cerebral ischemia, or cerebral infarction resulting from thromboembolic or hemorrhagic stroke, cerebral vasospasms, hypoglycemia, cardiac arrest, status epilepticus, perinatal asphyxia, anoxia, seizure disorders, pain, Alzheimer's, Parkinson's, and Huntington's Diseases.

Cyclic amine derivatives of substituted quinoxaline 2,3-diones as

Sulfonamide derivatives of substituted quinoxaline 2,3-diones as

A novel series of substituted quinoxaline 2,3-diones of Formula I ##STR1## useful as neuroprotective agents are taught. Novel intermediates, processes of preparation, and pharmaceutical compositions containing the compounds are also taught. The compounds are glutamate antagonists and are useful in the treatment of stroke, cerebral ischemia, or cerebral infarction resulting from thromboembolic or hemorrhagic stroke, cerebral vasospasms, hypoglycemia, cardiac arrest, status epilepticus, perinatal asphyxia, anoxia, seizure disorders, pain, Alzheimer's, Parkinson's, and Huntington's Diseases.

Novel quinazoline inhibitors of endothelin converting enzyme are described, as well as methods for the preparation and pharmaceutical compositions of the same, which are useful in treating elevated levels of endothelin and in controlling hypertension, myocardial infarction and ischemia, metabolic, endocrinological, and neurological disorders, congestive heart failure, endotoxic and hemorrhagic shock, septic shock, subarachnoid hemorrhage, arrhythmias, asthma, acute and chronic renal failure, cyclosporin-A induced nephrotoxicity, angina, gastric mucosal damage, ischemic bowel disease, cancer, pulmonary hypertension, preeclampsia, atherosclerotic disorders including Raynaud's disease and restenosis, cerebral ischemia and vasospasm, and diabetes.

Quinazolines as inhibitors of endothelin converting enzyme

Hydroxamate compounds of the following formula are disclosed:

Hydroxamate inhibitors of endothelin converting enzyme

A novel series of substituted quinoxaline 2,3-diones useful as neuroprotective agents are taught. Novel intermediates, processes of preparation, and pharmaceutical compositions containing the compounds are also taught. The compounds are glutamate antagonists and are useful in the treatment of stroke, cerebral ischemia, or cerebral infarction resulting from thromboembolic or hemorrhagic stroke, cerebral vasospasms, hypoglycemia, cardiac arrest, status epilepticus, perinatal asphyxia, anoxia, Alzheimer's, Parkinson's, and Huntington's diseases.

Alkyl amine derivatives of substituted quinoxaline 2,3-diones as

Growing community of inventors

Ann Arbor, MI, United States of America

Brian Edward Kornberg